After evaluating hFVIII activity and immunogenicity of the transgene in a mouse model of hemophilia A (FVIII knockout [KO] mice), we performed an additional capsid-specific immunogenicity evaluation.6 Based on our analyses, we selected AAVrh10 and AAVhu37 capsids and the E03.TTR and E12.A1AT enhancer/promoter combinations for further evaluation in nonhuman primates.11 This evidence concerns the gene TTR and hemophilia A.